Introduction The cost-effectiveness of treatments for chronic obstructive pulmonary disease (COPD) is needed.
Objectives To evaluate the cost effectiveness of once-daily umeclidinium bromide 62.5 µg (UMEC) in combination with inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) versus other long-acting muscarinic antagonists (LAMA)+ICS/LABA triple therapy combinations in the United Kingdom (UK).
Methods A linked-equation model estimated the disease progression, associated health service costs, and impact on quality-adjusted life-years and survival (Briggs et al. Med Decis Making 2016). Statistical risk equations for clinical endpoints and resource use were derived from the ECLIPSE and TORCH studies, respectively. Model baseline inputs and treatment effects were obtained from a network meta-analysis (Chounta et al. ATS 2016). For the base case, a lifetime horizon was used and costs and effects were discounted at 3.5%. Analyses were performed from the UK National Health Service perspective.
Results
UMEC+ICS/LABA improved health outcomes versus other LAMA+ICS/LABA combinations with lower costs over the lifetime. Results remained consistent at a 5- or 10-year time horizon. Sensitivity analyses showed that variation in main parameters did not alter the results.
Conclusions In COPD, UMEC+ICS/LABA is cost saving and improves health outcomes versus other LAMA+ICS/LABA triple combinations in the UK.
Funding GSK (HO-15-8059)